JAK Inhibitor News: Upadacitinib Now Available for Pediatric Patients with PsA, pJIA
Upadacitinib (Rinvoq, AbbVie) is now available in the U.S. as a tablet or an oral solution for the treatment of pediatric patients aged 2 and older with active psoriatic arthritis (PsA) as well as polyarticular juvenile idiopathic arthritis (pJIA), provided patients have had an inadequate response or intolerance to one or more tumor necrosis factor […]